Article
Rare emergence of drug resistance in HIV-1 treatment-naïve patients receiving elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide for 144 weeks.
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology - 1 Jun 2018
Margot Nicolas, Cox Stephanie, Das Moupali, McCallister Scott, Miller Michael D, Callebaut Christian
Abstract excerpt
BACKGROUND: The single tablet regimen (STR) composed of elvitegravir (E), cobicistat (C), emtricitabine (F), and tenofovir alafenamide (TAF) (E/C/F/TAF) was compared to the STR composed of E, C, F, and tenofovir disoproxil fumarate (TDF) (E/C/F/TDF) in 2 phase 3 studies in 1733 HIV-1 infected treatment-naïve adults. Superior efficacy of E/C/F/TAF compared to E/C/F/TDF was demonstrated at Week 144 with 84%...
Topics
Join the communities discussing this publication.